Evifacotrep

CAS No. 2413739-88-3

Evifacotrep( —— )

Catalog No. M28273 CAS No. 2413739-88-3

Evifacotrep, a short transient receptor potential channel 5 ( TRPC5 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 Get Quote
10MG 335 Get Quote
25MG 566 Get Quote
50MG 806 Get Quote
100MG 1098 Get Quote
500MG 2205 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Evifacotrep
  • Note
    Research use only, not for human use.
  • Brief Description
    Evifacotrep, a short transient receptor potential channel 5 ( TRPC5 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases .
  • Description
    Evifacotrep, a short transient receptor potential channel 5 ( TRPC5 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases .(In Vitro):Evifacotrep is a short transient receptor potential channel 5 ( TRPC5 ) antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    TRP/TRPV Channel
  • Recptor
    Raf|KRAS
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2413739-88-3
  • Formula Weight
    441.77
  • Molecular Formula
    C18H12ClF4N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (113.18 mM)
  • SMILES
    O=C1NN=CC(N2Cc3ncnc(Oc(cc4)c(C(F)(F)F)cc4F)c3CC2)=C1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Huestis MP, et al. Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. ACS Med Chem Lett. 2021 Apr 21;12(5):791-797.
molnova catalog
related products
  • JNJ-38893777

    JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain.

  • UNC-2025

    UNC-2025( IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.

  • HhAntag

    HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.